:
Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disease and
the most common cause of dementia among older adults. There are no effective treatments avail-
able for the disease, and it is associated with great societal concern because of the substantial costs
of providing care to its sufferers, whose numbers will increase as populations age. While multiple
causes have been proposed to be significant contributors to the onset of sporadic AD, increased age
is a unifying risk factor. In addition to amyloid-β (Aβ) and tau protein playing a key role in the initi-
ation and progression of AD, impaired mitochondrial bioenergetics and dynamics are likely major
etiological factors in AD pathogenesis and have many potential origins, including Aβ and tau. Mito-
chondrial dysfunction is evident in the central nervous system (CNS) and systemically early in the
disease process. Addressing these multiple mitochondrial deficiencies is a major challenge of mito-
chondrial systems biology. We review evidence for mitochondrial impairments ranging from mito-
chondrial DNA (mtDNA) mutations to epigenetic modification of mtDNA, altered gene expres-
sion, impaired mitobiogenesis, oxidative stress, altered protein turnover and changed organelle dy-
namics (fission and fusion). We also discuss therapeutic approaches, including repurposed drugs,
epigenetic modifiers, and lifestyle changes that target each level of deficiency which could poten-
tially alter the course of this progressive, heterogeneous Disease while being cognizant that success-
ful future therapeutics may require a combinatorial approach.